Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zelos Therapeutics has reported good results from a phase II study of its parathyroid hormone analogue Ostabolin-C, in postmenopausal women with osteoporosis.
Subscribe to our email newsletter
Ostabolin-C has demonstrated strong bone building activity in preclinical studies.
Ostabolin-C met the primary objective of this 4 month study by demonstrating a highly statistically significant, dose responsive increase in mean lumbar spine bone mineral density, that reached 5.2% at the highest dose tested. Ostabolin-C was generally well tolerated.
“Ostabolin-C has the potential to be uniquely positioned among osteoporosis treatments as an agent that can rapidly increase bone mass. Bone building therapies such as this are increasingly needed for the large and growing number of people who have already lost large amounts of bone as a result of osteoporosis and are at high and imminent risk of sustaining a fracture.” commented Brian MacDonald, CEO of Zelos.